According to an Oct. 18 research note by Maxim analyst Anthony Vendetti, Viveve Medical Inc.'s (VIVE:NASDAQ) preliminary Q3/17 revenue of about $4.1 million was "up roughly 122% year over year, relatively in line with our estimate of $4.2M and above consensus of $3.7M."
Based on the quarter's results, Vendetti concluded, "We would continue to be buyers of Viveve after announcing preliminary Q3/17 revenue above the consensus estimate."
The analyst noted this women's health and wellness company "continues to build its installed base and make progress with additional international regulatory clearances."
For instance, in Q3/17, the company shipped 60 Geneveve systems, taking the number of installed machines to 365, and sold approximately 2,700 related consumables.
Additionally, Viveve "announced new regulatory clearances for the product in five additional countries," Vendetti said. Those are Bahrain, Kuwait, Qatar and Mexico for the treatment of vaginal laxity, and Taiwan for electrocoagulation to achieve hemostasis during surgery.
The biotech also continues to advance its clinical program, Vendetti indicated. It is preparing to submit an investigational device exemption request to the FDA so it may start its Viveve II clinical study. "Barring any regulatory hurdles, we expect the company to commence its Phase 3 trial by 2017E, with a readout of data projected for mid-2019," Vendetti wrote.
In the United States, the Geneveve device is "currently cleared for electrocoagulation and hemostasis," the analyst explained. "In our opinion, the possibility of gaining an expanded FDA approval for the improvement of female sexual function represents the major growth opportunity for the company."
Following Viveve's announcement of its Q3/17 revenue, Maxim Group changed its projected earnings estimate for the company from $15.1 million to $15.2 million but left all other estimates "relatively unchanged," Vendetti said.
Maxim has a Buy rating and $11 per share 12-month target price on Viveve, whose stock is now trading at around $5.53 per share.
The company's Q3/17 earnings call is scheduled for Wednesday, Nov. 8, 2017, at 5 p.m. ET.
Read what other experts are saying about:
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Viveve Medical. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Viveve Medical, a company mentioned in this article.
Disclosures from Maxim Group, Viveve Medical, Oct. 18, 2017
I, Anthony Vendetti, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.
The research analyst(s) primarily responsible for the preparation of this research report have received compensation based upon various factors, including the firm’s total revenues, a portion of which is generated by investment banking activities.
Maxim Group makes a market in Viveve Medical, Inc.
Maxim Group managed/co-managed/acted as placement agent for an offering of the securities for Viveve Medical, Inc. in the past 12 months.
Maxim Group received compensation for investment banking services from Viveve Medical, Inc. in the past 12 months.Maxim Group expects to receive or intends to seek compensation for investment banking services from Viveve Medical, Inc. in the next 3 months.